We found that genetic ablation or pharmacologic inhibition of IRP2 disrupts cellular iron homeostasis and represses colon cancer cell growth in diverse model systems, including patient-derived cell lines, organoids, and tumor xenografts, thereby highlighting the feasibility of targeting IRP2 in CRC. Here, IREB2 is linked to colonic neoplasm.